Safety and Feasibility of Dasatinib and Quercetin in Adults at Risk for Alzheimer's Disease
Status:
Recruiting
Trial end date:
2023-06-01
Target enrollment:
Participant gender:
Summary
The purpose of this pilot study is to demonstrate the safety and feasibility of administering
intermittent doses of Dasatinib and Quercetin (D+Q) in older adults at risk of Alzheimer's
disease (AD). The study will evaluate whether giving D+Q may improve cerebral blood flow
regulation, mobility, and cognition in older adults, and thus may prevent progression to
Alzheimer's disease.